Common side effects during this period can include nausea, diarrhea, constipation, and vomiting
However, they are typically used alongside lifestyle approaches, such as dietary and exercise changes
The expected metabolic effect it lists is an improved metabolic rate and reduced visceral fat, with variability rated moderate to high depending on a person's fitness baseline
What Makes Retatrutide Different Retatrutide is a triple-agonist medication, meaning it acts on three different hormone receptors in the body: glucagon-like peptide-1 (GLP-1), gastric inhibitory polypeptide (GIP), and glucagon (GCG)
approval code 201901/01, date of approval: 2 May 2019)